
PCD Franchise for Ofloxacin & Dexamethasone Eye Drops | OXAONE-D | A1 Cure
PCD Franchise for Ofloxacin 0.3% w/v & Dexamethasone 0.1% w/v Eye Drops:- The ophthalmic pharmaceutical sector is one of the fastest-growing segments in the healthcare industry. Increasing cases of bacterial eye infections, eye allergies, inflammation, and post-surgical eye care requirements have significantly boosted the demand for combination eye drop formulations. Among the most commonly prescribed ophthalmic medicines is Ofloxacin 0.3% w/v & Dexamethasone 0.1% w/v Eye Drops, a powerful combination used for managing bacterial eye infections accompanied by inflammation.
To cater to this growing demand, A1 Cure (Division of Life Pharma Distributor) offers an excellent PCD Pharma Franchise for OXAONE-D, a premium ophthalmic formulation trusted for quality, effectiveness, and business growth opportunities.
📱 Call/WhatsApp: +91 9878911111
🌐 Website: www.lifepharma.in
📧 Email: sales@lifepharma.in
OXAONE-D Eye Drops combines a broad-spectrum antibacterial agent with an anti-inflammatory corticosteroid, making it a preferred choice for ophthalmic healthcare professionals.
Each ml contains:
This dual-action formulation helps address bacterial eye infections while supporting the reduction of inflammation and discomfort.
The combination formulation offers multiple therapeutic advantages.
✔ Broad-spectrum antibacterial support
✔ Helps manage bacterial eye infections
✔ Supports reduction of inflammation and redness
✔ Helps relieve eye discomfort and irritation
✔ Suitable for post-operative ophthalmic care under medical supervision
✔ Convenient ophthalmic dosage form
✔ High demand among ophthalmologists and eye care specialists
Healthcare professionals may prescribe OXAONE-D for:
Note: This medication should be used only under the supervision of a qualified healthcare professional.
The ophthalmology market continues to expand rapidly due to several factors.
Pollution, dust exposure, and changing environmental conditions have increased the prevalence of eye infections.
Extended screen exposure contributes to eye strain, dryness, and irritation, increasing the need for ophthalmic care.
The number of eye hospitals, specialty clinics, and vision centers is growing throughout India.
People are becoming increasingly aware of the importance of timely eye treatment and preventive care.
The ophthalmic segment offers tremendous growth opportunities for pharmaceutical entrepreneurs.
Eye infections and inflammatory conditions affect people of all age groups.
Ophthalmologists frequently prescribe antibiotic-steroid combinations for appropriate cases.
The eye care sector continues to grow across urban and rural markets.
Franchise partners can benefit from competitive pricing and strong returns.
Eye care products generate regular demand through healthcare channels.
A1 Cure has established itself as a trusted pharmaceutical company by providing quality products and comprehensive franchise support.
✔ Monopoly Rights Availability
✔ Quality-Assured Ophthalmic Products
✔ Competitive Pricing Structure
✔ Wide Product Portfolio
✔ Timely Delivery System
✔ Attractive Promotional Inputs
✔ Professional Business Support
✔ Long-Term Growth Opportunities
A1 Cure helps franchise partners build a strong market presence through:
Therefore, franchise associates receive the tools needed to expand their business efficiently.
This opportunity is suitable for:
Applicants generally require:
Starting your franchise business is simple:
Contact A1 Cure.
Discuss territory and product requirements.
Submit necessary business documents.
Confirm monopoly rights availability.
Place your first order and begin operations.
India’s eye care industry is expected to grow steadily in the coming years. Rising healthcare awareness, technological advancements, and improved access to ophthalmic treatments are creating new business opportunities. Consequently, products like OXAONE-D Eye Drops can play an important role in building a successful ophthalmic franchise business.
The combination of Ofloxacin and Dexamethasone remains one of the most prescribed ophthalmic categories in clinical practice. Since bacterial eye infections often involve inflammation, healthcare professionals frequently rely on combination formulations that address both concerns. As a result, OXAONE-D offers strong market potential and consistent demand.
The ophthalmic market in India continues to present excellent opportunities for pharmaceutical distributors and entrepreneurs. OXAONE-D Eye Drops, containing Ofloxacin 0.3% w/v & Dexamethasone 0.1% w/v, represent a valuable product category with growing demand across healthcare settings.
By partnering with A1 Cure, franchise associates gain access to quality products, monopoly rights, promotional support, and long-term business opportunities.
📱 Call/WhatsApp: +91 9878911111
🌐 Website: www.lifepharma.in
📧 Email: sales@lifepharma.in
OXAONE-D is an ophthalmic formulation containing Ofloxacin 0.3% w/v and Dexamethasone 0.1% w/v.
Ofloxacin is a broad-spectrum antibacterial agent commonly used in ophthalmic formulations.
Dexamethasone is a corticosteroid that helps manage inflammation under medical supervision.
Healthcare professionals may prescribe it for bacterial eye infections associated with inflammation.
Distributors, wholesalers, stockists, MRs, and healthcare entrepreneurs can apply.
Yes, monopoly rights are available depending on territory availability.
A1 Cure provides visual aids, product literature, reminder cards, samples, and marketing materials.
Yes, ophthalmic products have strong demand and significant growth potential in India.
Drug License, GST Registration, PAN Card, Aadhaar Card, and address proof are generally required.
Simply contact A1 Cure, submit the required documents, discuss your territory, and begin your franchise business.
